Please login to the form below

Not currently logged in
Email:
Password:

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  
 FDA building

The US FDA has approved Bristol-Myers Squibb's Evotaz in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

Evotaz combines BMS' Reyataz (atazanavir) with Gilead Science's boosting agency cobicistat as part of a once-daily pill to be taken over a 48-week course.

The treatment is the outcome of an agreement made between BMS and Gilead in 2011, when they agreed to develop and market a fixed-dose combination HIV treatment

Murdo Gordon, head of worldwide markets at BMS, commented: “Evotaz increases the possibility of providing HIV suppression by combining reduced pill burden with a low rate of virologic failure and zero protease inhibitor mutations.”

Cobicistat is already a crucial part of several HIV treatments, including Rezolsta/Prezcobix, which pairs the drug with Janssen's Prezista (darunavir), and Gilead's own combination therapy Stribild.

Reyataz is also a successful monotherapy treatment for HIV managing worldwide revenues of more than $1bn for the first nine months of 2014.

BMS is responsible for the manufacturing and sale of the cobicistat-boosted eyataz product and will pay Gilead royalties on sales.

 

Article by
Kirstie Pickering

2nd February 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics